JPWO2020206320A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020206320A5 JPWO2020206320A5 JP2021558657A JP2021558657A JPWO2020206320A5 JP WO2020206320 A5 JPWO2020206320 A5 JP WO2020206320A5 JP 2021558657 A JP2021558657 A JP 2021558657A JP 2021558657 A JP2021558657 A JP 2021558657A JP WO2020206320 A5 JPWO2020206320 A5 JP WO2020206320A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- pharmaceutical composition
- acid sequence
- seq
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962828859P | 2019-04-03 | 2019-04-03 | |
| US62/828,859 | 2019-04-03 | ||
| US201962832032P | 2019-04-10 | 2019-04-10 | |
| US62/832,032 | 2019-04-10 | ||
| PCT/US2020/026669 WO2020206320A1 (fr) | 2019-04-03 | 2020-04-03 | Formulations de molécules protéiques comprenant de l'iduronate 2-sulfatase |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022526799A JP2022526799A (ja) | 2022-05-26 |
| JPWO2020206320A5 true JPWO2020206320A5 (fr) | 2023-04-03 |
Family
ID=70457135
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021558657A Pending JP2022526799A (ja) | 2019-04-03 | 2020-04-03 | イズロン酸２－スルファターゼを含むタンパク質分子の製剤 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20220184186A1 (fr) |
| EP (1) | EP3947661A1 (fr) |
| JP (1) | JP2022526799A (fr) |
| KR (1) | KR20220004651A (fr) |
| CN (1) | CN113785054A (fr) |
| AU (1) | AU2020252554A1 (fr) |
| BR (1) | BR112021019520A2 (fr) |
| CA (1) | CA3134538A1 (fr) |
| MX (1) | MX2021011612A (fr) |
| WO (1) | WO2020206320A1 (fr) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI3583120T3 (fi) | 2017-02-17 | 2023-01-13 | Muunneltuja transferriinireseptoria sitovia polypeptidejä | |
| KR20200058510A (ko) | 2017-10-02 | 2020-05-27 | 데날리 테라퓨틱스 인크. | 효소 대체 요법 효소를 포함하는 융합 단백질 |
| BR112020022610A2 (pt) | 2018-05-10 | 2021-02-09 | Regeneron Pharmaceuticals, Inc. | proteína de fusão de receptor de vegf de alta concentração que contém formulações |
| EP3699923A1 (fr) * | 2019-02-20 | 2020-08-26 | Fresenius Medical Care Deutschland GmbH | Mécanisme de sécurité pour le fonctionnement d'appareils médicaux à l'aide d'objets de consommation dans un environnement d'une dialyse |
| AU2020411480B2 (en) | 2019-12-23 | 2023-12-21 | Denali Therapeutics Inc. | Progranulin variants |
| PE20221465A1 (es) | 2020-01-13 | 2022-09-21 | Denali Therapeutics Inc | Anticuerpos anti-trem2 y metodos para utilizarlos |
| CR20230178A (es) | 2020-10-14 | 2023-07-26 | Denali Therapeutics Inc | Proteínas de fusión que comprenden enzimas sulfoglucosamina sulfohidrolasa y métodos de estas |
| WO2023004156A1 (fr) | 2021-07-23 | 2023-01-26 | Denali Therapeutics Inc. | Procédés de traitement de la maladie de hunter |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2485761T3 (da) * | 2009-10-09 | 2019-05-06 | Armagen Inc | Fremgangsmåder og sammensætninger til øgning af iduronat-2-sulfatase-aktivitet i CNS |
| WO2015009052A1 (fr) * | 2013-07-16 | 2015-01-22 | 일동제약 주식회사 | Protéine de fusion de fc hybride d'immunoglobuline et d'enzyme |
| KR20180071193A (ko) * | 2016-12-19 | 2018-06-27 | 한미약품 주식회사 | 뇌 표적 지속성 단백질 결합체 |
| WO2019022563A2 (fr) * | 2017-07-28 | 2019-01-31 | 한미약품 주식회사 | Conjugué d'iduronate-2-sulfatase |
| KR20200058510A (ko) * | 2017-10-02 | 2020-05-27 | 데날리 테라퓨틱스 인크. | 효소 대체 요법 효소를 포함하는 융합 단백질 |
-
2020
- 2020-04-03 CA CA3134538A patent/CA3134538A1/fr active Pending
- 2020-04-03 MX MX2021011612A patent/MX2021011612A/es unknown
- 2020-04-03 EP EP20721359.6A patent/EP3947661A1/fr active Pending
- 2020-04-03 BR BR112021019520A patent/BR112021019520A2/pt unknown
- 2020-04-03 US US17/600,527 patent/US20220184186A1/en active Pending
- 2020-04-03 JP JP2021558657A patent/JP2022526799A/ja active Pending
- 2020-04-03 AU AU2020252554A patent/AU2020252554A1/en active Pending
- 2020-04-03 WO PCT/US2020/026669 patent/WO2020206320A1/fr unknown
- 2020-04-03 KR KR1020217035336A patent/KR20220004651A/ko unknown
- 2020-04-03 CN CN202080033104.6A patent/CN113785054A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20190071496A1 (en) | Pharmaceutical formulations of tnf-alpha antibodies | |
| JP5235661B2 (ja) | 安定化ポリペプチド製剤 | |
| TWI548424B (zh) | 依那西普之安定的液體調配劑 | |
| JP6385345B2 (ja) | 持続型インスリン分泌性ペプチド結合体の液状製剤 | |
| JP5873854B2 (ja) | 凍結乾燥された治療用ペプチボディ製剤 | |
| TWI605824B (zh) | 長效胰島素接合物之液體調配劑 | |
| WO2011012637A4 (fr) | Formulation sous-cutanée d'anticorps anti-her2 | |
| TW201021825A (en) | Lyophilized recombinant VWF formulations | |
| NO327302B1 (no) | Lagringsstabil sammensetning, forseglet ror eller patron inneholdende nevnte sammensetning samt fremgangsmate for deres fremstilling | |
| WO2018121457A1 (fr) | Application pharmaceutique d'un polypeptide dans la prévention ou le traitement de maladies associées aux lésions d'ischémie-reperfusion myocardique | |
| US20220184186A1 (en) | Formulations of protein molecules comprising iduronate 2-sulfatase | |
| JP4053586B2 (ja) | ガンマインターフェロンの安定液体組成物 | |
| JPWO2020206320A5 (fr) | ||
| CN114126584A (zh) | 重组蛋白质稳定制剂 | |
| JP2024003211A (ja) | 組換えヒト副甲状腺ホルモンの安定性を向上させるための製剤 | |
| KR20210078514A (ko) | 항-rsv 항체의 제제 및 그의 사용 방법 | |
| JPH10330284A (ja) | 肝細胞保護剤 | |
| EA026073B1 (ru) | Состав бычьего гранулоцитарного колониестимулирующего фактора и способ лечения с его использованием | |
| EP2825192B1 (fr) | Proteines pour l'induction de la croissance dirigée des vaisseaux sanguins et leurs applications | |
| KR20230165799A (ko) | L-아스파라기나제의 제제 | |
| WO2022166918A1 (fr) | Formulation d'anticorps anti-il-5, son procédé de préparation et son utilisation |